$2.19
+0.38 (+20.99%)
Open$1.85
Previous Close$1.81
Day High$2.26
Day Low$1.82
52W High$7.20
52W Low$1.14
Volume—
Avg Volume1.03M
Market Cap284.97M
P/E Ratio—
EPS$-0.72
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+1,871.7% upside
Current
$2.19
$2.19
Target
$43.18
$43.18
$31.72
$43.18 avg
$59.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 34.78M | 32.14M | 39.05M |
| Net Income | 5.77M | 7.01M | 8.10M |
| Profit Margin | 16.6% | 21.8% | 20.7% |
| EBITDA | 11.08M | 11.55M | 13.91M |
| Free Cash Flow | 4.11M | 3.56M | 7.02M |
| Rev Growth | +3.0% | +6.5% | +17.8% |
| Debt/Equity | 0.16 | 0.15 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |